| 2025-01-13 | +111.5% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2025-01-13 | +111.5% | news | timothysykes.com | Phio Pharmaceuticals’ Stock Skyrockets: Is the Surge Here to Stay? - timothysykes.com |
| 2025-01-14 | -61.7% | news | Seeking Alpha | Phio Pharmaceuticals sharply lower on equity offering |
| 2025-01-14 | -61.7% | legal | SEC EDGAR | PHIO 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-01-14 | -61.7% | news | Stocktwits | We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run - Stocktwits |
| 2025-04-09 | +57.7% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2026-02-10 | +43.6% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2023-04-18 | -32.9% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2024-12-19 | -30.7% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2024-12-20 | +26.7% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2022-11-10 | -23.9% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2026-02-18 | -22.7% | legal | SEC EDGAR | PHIO 8-K: 5.02 (SEC Filing) |
| 2024-07-12 | -21.0% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-01-15 | -20.3% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-11-03 | -19.5% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2025-11-03 | -19.5% | news | Stock Titan | Phio (NASDAQ: PHIO) to get $13.4M as 5.66M warrants exercised in two tranches - Stock Titan |
| 2025-05-28 | +19.5% | news | Zacks Investment Research | Should I buy Phio Pharmaceuticals (PHIO) - Zacks Investment Research |
| 2025-01-21 | -18.8% | news | Seeking Alpha | Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders |
| 2025-01-17 | -16.7% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2023-05-31 | -16.5% | news | Seeking Alpha | Phio Pharmaceuticals slides on equity offering |
| 2025-11-13 | -16.0% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$0.44 beats by $0.01 |
| 2025-11-13 | -16.0% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2025-11-13 | -16.0% | news | TMX Newsfile | Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - TMX Newsfile |
| 2023-02-10 | -15.5% | news | Seeking Alpha | Phio gets monitoring panel's nod to advance enrolling in skin cancer trial after data review |
| 2024-07-02 | -14.7% | legal | SEC EDGAR | PHIO 8-K: 3.03, 5.03, 8.01 (SEC Filing) |
| 2024-07-02 | -14.7% | news | Yahoo Finance | Phio Pharmaceuticals Announces Reverse Stock Split - Yahoo Finance |
| 2023-05-24 | -13.5% | news | Seeking Alpha | Phio stock rises ~12% as cancer drug trial set for patient enrollment |
| 2023-05-24 | -13.5% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2023-05-11 | -13.3% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$3.15 |
| 2023-05-11 | -13.3% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2024-05-09 | -12.6% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2024-08-15 | +11.8% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$3.62 beats by $0.52 |
| 2026-02-19 | -11.7% | news | Stock Titan | Phio reshapes leadership as PH-762 cancer drug nears key tests - Stock Titan |
| 2022-11-16 | -11.6% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 3.03, 5.03 (SEC Filing) |
| 2023-03-10 | +11.5% | legal | SEC EDGAR | PHIO 8-K: 8.01 (SEC Filing) |
| 2024-12-26 | -11.2% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2023-05-16 | +11.0% | legal | Seeking Alpha | Phio Pharma's lead candidate, PH-762, receives FDA clearance for clinical trial, shares surge by 28% |
| 2023-05-16 | +11.0% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2024-11-07 | -10.7% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2024-05-10 | -10.3% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$0.47 |
| 2025-06-12 | -10.3% | legal | SEC EDGAR | PHIO 8-K: 5.02 and (SEC Filing) |
| 2025-10-31 | -10.2% | legal | SEC EDGAR | PHIO 8-K: 5.02, 8.01 (SEC Filing) |
| 2022-05-10 | -10.0% | legal | SEC EDGAR | PHIO 8-K: 5.02 (SEC Filing) |
| 2021-05-13 | -9.6% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2024-07-05 | +8.7% | expansion | Seeking Alpha | Phio Pharmaceuticals terminates share purchase agreement with Triton Funds |
| 2024-07-05 | +8.7% | legal | SEC EDGAR | PHIO 8-K: 1.02, 8.01 (SEC Filing) |
| 2022-08-11 | -8.3% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2023-06-02 | -8.1% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2026-01-20 | -7.9% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2026-04-09 | -7.4% | news | TMX Newsfile | Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 |
| 2026-04-09 | -7.4% | executive | Stock Titan | Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation - Stock Titan |
| 2026-04-09 | -7.4% | expansion | Minichart | Phio Pharmaceuticals Corp. Enters Material Definitive Agreement – SEC 8-K Filing Details April 8, 2026 - Minichart |
| 2026-03-16 | +7.3% | news | TMX Newsfile | Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office |
| 2026-03-16 | +7.3% | executive | Stock Titan | Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan |
| 2024-05-17 | +6.8% | legal | Seeking Alpha | Phio Pharmaceuticals files for $100M mixed securities shelf |
| 2024-05-17 | +6.8% | legal | SEC EDGAR | PHIO 8-K: 1.01, 8.01 (SEC Filing) |
| 2023-02-13 | -6.7% | news | Seeking Alpha | Phio Pharmaceuticals regains compliance with Nasdaq listing rules |
| 2023-02-13 | -6.7% | legal | SEC EDGAR | PHIO 8-K: 8.01 (SEC Filing) |
| 2021-08-12 | -6.5% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2023-11-09 | -6.0% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29 |
| 2023-11-09 | -6.0% | legal | SEC EDGAR | PHIO 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-07-30 | -5.8% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2022-03-22 | +5.8% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2026-03-30 | -5.7% | expansion | TMX Newsfile | Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 |
| 2026-03-30 | -5.7% | legal | SEC EDGAR | PHIO 8-K: 8.01 (SEC Filing) |
| 2024-04-02 | +5.6% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$5.20 |
| 2024-04-02 | +5.6% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2025-03-31 | -5.6% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$9.08 misses by $0.54 |
| 2025-03-31 | -5.6% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2024-08-01 | -5.4% | executive | Seeking Alpha | Phio Pharmaceuticals appoints Robert Infarinato as chief financial officer |
| 2024-08-01 | -5.4% | legal | SEC EDGAR | PHIO 8-K: 5.02 and (SEC Filing) |
| 2025-12-23 | -5.4% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2026-04-23 | -5.2% | M&A | TMX Newsfile | Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series |
| 2026-04-23 | -5.2% | news | Stock Titan | Cancer drug developer Phio sets April 29 live Q&A on clinical progress - Stock Titan |
| 2023-04-20 | -5.2% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2023-04-20 | -5.2% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02 (SEC Filing) |
| 2023-12-08 | -5.2% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-07-07 | +5.0% | legal | SEC EDGAR | PHIO 8-K: 8.01 (SEC Filing) |
| 2024-07-24 | +4.8% | legal | SEC EDGAR | PHIO 8-K: 8.01 (SEC Filing) |
| 2025-04-25 | -4.8% | news | Stock Titan | Phio Pharmaceuticals Stock Price, News & Analysis - Stock Titan |
| 2023-04-17 | -4.8% | news | Seeking Alpha | Phio Pharma rises 11% on positive data from preclinical study of PH-762 to treat melanoma |
| 2023-04-17 | -4.8% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2023-03-22 | +4.6% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$10.10 beats by $0.82 |
| 2023-03-22 | +4.6% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2023-08-21 | -4.6% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2023-01-25 | +4.5% | news | Seeking Alpha | Phio Pharma falls 10% on 1-for-12 reverse stock split |
| 2023-01-25 | +4.5% | legal | SEC EDGAR | PHIO 8-K: 3.03, 5.03, 8.01 (SEC Filing) |
| 2026-04-14 | +4.4% | news | TMX Newsfile | Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 - TMX Newsfile |
| 2026-03-10 | +4.4% | news | GlobeNewswire | Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th |
| 2026-03-10 | +4.4% | news | GlobeNewswire | Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT |
| 2026-04-13 | +4.4% | news | TMX Newsfile | Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 |
| 2025-11-25 | +4.4% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2023-08-10 | -4.3% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$1.47 |
| 2023-08-10 | -4.3% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2025-09-03 | -4.2% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2021-11-10 | -4.0% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2024-11-14 | -4.0% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2024-05-20 | -3.8% | news | Seeking Alpha | Phio Pharmaceuticals files for $100M mixed shelf |
| 2024-08-14 | -3.6% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2025-05-07 | +3.5% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2026-03-05 | +2.7% | news | TMX Newsfile | Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update |
| 2026-03-05 | +2.7% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$1.45 beats by $0.31 |
| 2026-03-05 | +2.7% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2026-03-05 | +2.7% | news | TMX Newsfile | Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - TMX Newsfile |
| 2026-03-05 | +2.7% | executive | Stock Titan | Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan |
| 2024-11-15 | +2.7% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$1.54 |
| 2023-07-26 | -2.4% | legal | SEC EDGAR | PHIO 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-04-08 | -2.3% | legal | SEC EDGAR | PHIO 8-K: 1.01 and (SEC Filing) |
| 2026-04-08 | -2.3% | news | TipRanks | Phio Pharmaceuticals Establishes New At-the-Market Equity Program - TipRanks |
| 2026-04-08 | -2.3% | expansion | Stock Titan | Phio Pharmaceuticals (NASDAQ: PHIO) launches $6.36M at-the-market stock plan - Stock Titan |
| 2026-04-08 | -2.3% | news | Stock Titan | Phio Pharmaceuticals (PHIO) files $6.36M ATM with H.C. Wainwright - Stock Titan |
| 2026-04-22 | -2.2% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | PHIO Phio Pharmaceuticals posts narrower than expected Q4 2025 loss as shares dip nearly 2 percent in today’s trading. - Interest Coverage - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-05-15 | -2.2% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$0.41 |
| 2025-05-15 | -2.2% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2025-02-20 | -1.9% | legal | SEC EDGAR | PHIO 8-K: 5.02, 8.01 (SEC Filing) |
| 2022-09-29 | -1.7% | legal | SEC EDGAR | PHIO 8-K: 5.02 and (SEC Filing) |
| 2025-08-15 | -1.6% | news | Seeking Alpha | Phio Pharmaceuticals files to sell 1.93M shares for holders |
| 2023-02-22 | -1.5% | executive | Seeking Alpha | Phio Pharmaceuticals names Robert Bitterman as CEO |
| 2023-02-22 | -1.5% | legal | SEC EDGAR | PHIO 8-K: 5.02 and (SEC Filing) |
| 2024-05-28 | -1.5% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2025-09-15 | -1.3% | legal | SEC EDGAR | PHIO 8-K: 5.02 and 5.07 (SEC Filing) |
| 2025-06-26 | -1.3% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2022-05-12 | +1.1% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |
| 2023-12-19 | +0.9% | news | Seeking Alpha | Phio Pharmaceuticals files to sell 4.42M shares of common stock for holders |
| 2022-12-21 | -0.9% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2026-03-23 | -0.7% | news | TMX Newsfile | Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement |
| 2025-07-25 | +0.4% | news | Seeking Alpha | Phio Pharmaceuticals stock jumps 24% on partnering with U.S. drug substance manufacturer |
| 2025-07-25 | +0.4% | legal | SEC EDGAR | PHIO 8-K: 8.01 and (SEC Filing) |
| 2024-06-21 | +0.4% | legal | SEC EDGAR | PHIO 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-03-13 | +0.4% | news | GlobeNewswire | Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing |
| 2025-11-06 | -0.3% | legal | SEC EDGAR | PHIO 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-08-14 | -0.2% | earnings | Seeking Alpha | Phio Pharmaceuticals GAAP EPS of -$0.45 |
| 2025-08-14 | -0.2% | legal | SEC EDGAR | PHIO 8-K: 2.02 and (SEC Filing) |